D. Glicklich et A. Acharya, MYCOPHENOLATE MOFETIL THERAPY FOR LUPUS NEPHRITIS REFRACTORY TO INTRAVENOUS CYCLOPHOSPHAMIDE, American journal of kidney diseases, 32(2), 1998, pp. 318-322
intravenous (IV) cyclophosphamide has been the treatment of choice for
diffuse proliferative glomerulonephritis (DPGN) in patients with syst
emic lupus erythematosus (SLE), However, there is little guidance in t
he medical literature about what to do when this therapy fails. Mycoph
enolate mofetil (MMF), a new immunosuppressive agent, has been used su
ccessfully in patients with solid organ transplants and rheumatoid art
hritis. We report two patients with diffuse proliferative glomerulonep
hritis who responded favorably to MMF therapy after IV cyclophosphamid
e failed. (C) 1998 by the National Kidney Foundation, Inc.